Literature DB >> 30517706

The relationship between remission and health-related quality of life in a cohort of SLE patients.

Michel W P Tsang-A-Sjoe1, Irene E M Bultink1, Maaike Heslinga1, Lilian H van Tuyl1, Ronald F van Vollenhoven1, Alexandre E Voskuyl1.   

Abstract

OBJECTIVE: To investigate the relationship between remission and health-related quality of life (HRQoL) in patients with SLE in a longitudinal observational cohort.
METHODS: HRQoL was measured at cohort visits using the physical and mental component score (PCS and MCS, respectively) of the Short Form 36 questionnaire. Definitions of Remission in SLE remission categories (no remission/remission on therapy/remission off therapy) were applied. Determinants of PCS and MCS were identified with simple linear regression analyses. Association between remission and HRQoL was assessed using generalized estimating equation models.
RESULTS: Data from 154 patients with 2 years of follow-up were analysed. At baseline 60/154 (39.0%) patients were in either form of remission. Patients in remission had higher Short Form 36 scores in all subdomains compared with patients not in remission. PCS was positively associated with remission and employment, and negatively associated with SLICC damage index, ESR, medication, patient global assessment and BMI. MCS was positively associated with Caucasian ethnicity and negatively associated with patient global assessment. In generalized estimating equation analysis, a gradual and significant increase of PCS was observed from patients not in remission (mean PCS 36.0) to remission on therapy (41.8) to remission off therapy (44.8). No significant difference in MCS was found between remission states.
CONCLUSION: we show a strong and persistent association between remission and PCS, but not MCS. These results support the relevance (construct validity) of the Definition of Remission in SLE remission definitions and the further development of a treat-to-target approach in SLE.
© The Author(s) 2018. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  health-related quality of life; remission; systemic lupus erythematosus; treat-to-target

Mesh:

Year:  2019        PMID: 30517706     DOI: 10.1093/rheumatology/key349

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  8 in total

1.  Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort.

Authors:  Manuel Francisco Ugarte-Gil; Guillermo J Pons-Estel; Luis M Vila; Gerald McGwin; Graciela S Alarcón
Journal:  RMD Open       Date:  2019-05-23

2.  The patient's perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?

Authors:  Anna Kernder; Elena Elefante; Gamal Chehab; Chiara Tani; Marta Mosca; Matthias Schneider
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

3.  Treatment targets in SLE: remission and low disease activity state.

Authors:  Vera Golder; Michel W P Tsang-A-Sjoe
Journal:  Rheumatology (Oxford)       Date:  2020-12-05       Impact factor: 7.580

4.  Adverse Health-Related Quality of Life Outcome Despite Adequate Clinical Response to Treatment in Systemic Lupus Erythematosus.

Authors:  Alvaro Gomez; Victor Qiu; Arvid Cederlund; Alexander Borg; Julius Lindblom; Sharzad Emamikia; Yvonne Enman; Jon Lampa; Ioannis Parodis
Journal:  Front Med (Lausanne)       Date:  2021-04-16

5.  Impact of demographic, clinical, and treatment compliance characteristics on quality of life of Venezuelan patients with systemic lupus erythematosus.

Authors:  Fhabián S Carrión-Nessi; María V Marcano-Rojas; Sinibaldo R Romero Arocha; Daniela L Mendoza Millán; David A Forero-Peña; Allen W Antuarez-Magallanes; Soham Al Snih; Martín A Rodríguez; Yurilís J Fuentes-Silva
Journal:  BMC Rheumatol       Date:  2022-01-04

6.  2021 DORIS definition of remission in SLE: final recommendations from an international task force.

Authors:  Ronald F van Vollenhoven; George Bertsias; Andrea Doria; David Isenberg; Eric Morand; Michelle A Petri; Bernardo A Pons-Estel; Anisur Rahman; Manuel Francisco Ugarte-Gil; Alexandre Voskuyl; Laurent Arnaud; Ian N Bruce; Ricard Cervera; Nathalie Costedoat-Chalumeau; Caroline Gordon; Frédéric A Houssiau; Marta Mosca; Matthias Schneider; Michael M Ward; Graciela Alarcon; Martin Aringer; Anka Askenase; Sang-Cheol Bae; Hendrika Bootsma; Dimitrios T Boumpas; Hermine Brunner; Ann Elaine Clarke; Cindy Coney; László Czirják; Thomas Dörner; Raquel Faria; Rebecca Fischer; Ruth Fritsch-Stork; Murat Inanc; Søren Jacobsen; David Jayne; Annegret Kuhn; Bernadette van Leeuw; Maarten Limper; Xavier Mariette; Sandra Navarra; Mandana Nikpour; Marzena Helena Olesinska; Guillermo Pons-Estel; Juanita Romero-Diaz; Blanca Rubio; Yehuda Schoenfeld; Eloisa Bonfá; Josef Smolen; Y K Onno Teng; Angela Tincani; Michel Tsang-A-Sjoe; Carlos Vasconcelos; Anne Voss; Victoria P Werth; Elena Zakharhova; Cynthia Aranow
Journal:  Lupus Sci Med       Date:  2021-11

7.  Chinese SLE Treatment and Research Group Registry (CSTAR) XIV: the subjective well-being of patients with systemic lupus erythematosus.

Authors:  Yue Shi; Dandan Bi; Yanhong Wang; Ruofan Li; Lijun Wu; Cheng Zhao; Zhenbiao Wu; Xinwang Duan; Jian Xu; Feng Zhan; Min Yang; Shengyun Liu; Qin Li; Shuo Zhang; Lingshan Liu; Jiuliang Zhao; Xinping Tian; Xinying Li; Qian Wang; Xiaofeng Zeng
Journal:  Front Med (Lausanne)       Date:  2022-09-20

8.  Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus.

Authors:  Elena Elefante; Chiara Tani; Chiara Stagnaro; Viola Signorini; Alice Parma; Linda Carli; Dina Zucchi; Francesco Ferro; Marta Mosca
Journal:  Arthritis Res Ther       Date:  2020-10-14       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.